H aemorrhagic diathesis is a common manifestation of acute leukaemia and is usually caused by thrombocytopenia. 1 Haemostatic disturbances seen in patients with acute leukaemia can be related to changes in vascular function, failure of the haematopoietic system, liver dysfunction, increased fibrinolysis, or disseminated intravascular coagulation (DIC). 2 In such patients, a spurious platelet count as a result of red blood cell fragmentation 3 or fragmentation of white blood cells [4] [5] [6] [7] [8] [9] [10] [11] has been reported previously. Stass et al reported a spurious increase in automated platelet counts in a patient with hairy cell leukaemia, with a significantly lower number of platelets being seen when counted microscopically. 5 Armitage et al described a patient with acute leukaemia who had artificially raised platelet counts because of circulating fragments of leukaemic cells. 6 Malcolm et al reported a case of spurious thrombocytosis in a patient with acute myelocytic leukaemia, who had thrombopenia when the blood smear was viewed under the microscope 7 ; the automated platelet count in this patient was 10 times higher than the microscopic count. Stass et al reported a case of spurious platelet counts caused by cell fragmentation in a patient with a poorly differentiated lymphoma; after chemotherapy the number of platelet-like fragments increased. 8 Hammerstrom 9 reported a patient with a newly diagnosed acute myeloid leukaemia (AML: FAB M5) with DIC, for which the patient was treated with low dose heparin. Although the platelet count was 129 × 10 9 /litre, the patient developed intracerebral bleeding and died. Staining the blood smears with platelet specific antigen resulted in only 4% positive cell particles, whereas one third of the particles showed the same staining characteristics as the leukaemia cells, indicating their leukaemic origin. Sugimoto et al reported a case of AML (FAB M2) with cell fragments resembling giant platelets positive for myeloperoxidase. 10 Finally, Li et al reported a patient with secondary acute monocytic leukaemia with tumour lysis syndrome; numerous fragments of leukaemic cells resulted in a falsely raised platelet count. 11 Moreover, apoptotic cells with pycnotic nuclei were seen, suggesting a relation between apoptosis and pseudoplatelets.
In our present study, we investigated 169 patients with leukaemia, both de novo diagnosed and relapsed (table 1).
Furthermore we looked at the bleeding tendency of patients with pseudoplatelets who are classified into the risk group for bleeding disorders after correction of the automated platelet count.
"Haemorrhagic diathesis is a common manifestation of acute leukaemia and is usually caused by thrombocytopenia"
To exclude the possibility that pseudoplatelets are an intrinsic result of the slide preparation method, both the correlation of pseudoplatelets with smudge cells and pseudoplatelets with leucocytosis was studied.
MATERIALS AND METHODS
Blood was obtained by venapuncture or by finger prick and anticoagulated with K 3 EDTA. Within four hours, the blood was measured for complete blood cell count (CBC) and a blood smear was made by the wedge method. The slides were stained according the May Grünwald-Giemsa method. Stained slides were embedded and stored in a dark place at room temperature. CBC was performed by an automated analyser: H*3 from Bayer (Tarrytown, New York, USA) or Sysmex NE-8000 from Toa (Kobe, Japan). The principle of platelet counting is based on flow cytometry (H*3) or impedance (NE-8000). Both platelets and erythrocytes are counted in the same channel: discrimination between platelets and erythrocytes is made on particle size.
The patients included in our study were diagnosed with acute leukaemia at onset or at relapse and had blast cells in the peripheral blood. Table 1 lists the various types of leukaemia, onset/relapse, age and sex of the patients. The acute leukaemias were further specified according the FAB classification 12 with the aid of immunophenotyping and cytochemistry.
A 500 particle differentiation was made of each sample (platelets, pseudoplatelets, leucocytes, and smear cells) and the percentage of pseudoplatelets was calculated. In cases of high white blood cell count, the platelets and pseudoplatelets were counted separately. Arbitrarily, if more than 5% pseudoplatelets were present the smear was considered positive for the presence of pseudoplatelets. These positive samples were also reviewed by an independent expert. Both manual counts were averaged and used to correct the platelet count. We used 15 × 10 9 /litre (the mean of 10 × 10 9 /litre and 20 × 10 9 /litre) as the cut off value for serious bleeding risk, as published previously. 13 14 /litre), the counts are usually reliable. However, in certain cases these analysers produce erroneous platelet results. Pseudothrombopenia is a well known phenomenon and via various procedures (for example, recounting platelets in citrated blood) the laboratory is able to produce a correct result. We report an opposite phenomenon with important clinical implications: pseudothrombocytosis or at least obvious overestimation of the real number of platelets in patients with acute leukaemia. Because of their shape and size, haematology analysers add several undefined particles to the platelet cluster. In some cases, this may even lead to the masking of a (possible life threatening) thrombopenia, and consequently the withholding of proper medication or other crucial supportive measures.
"To establish a proper platelet count, we suggest that the blood smears at presentation and at unexpected bleeding disorders in patients with acute leukaemia (de novo or relapsed) should be examined for pseudoplatelets"
The undefined particles (or pseudoplatelets) are not formed as a result of mechanical destruction during the preparation of the smear. No correlation was found between the number and presence of smudge cells and the number and presence of pseudoplatelets, indicating a different origin.
To establish a proper platelet count, we suggest that the blood smears made at presentation and at unexpected bleeding disorders in patients with acute leukaemia (de novo or relapsed) should be examined for pseudoplatelets. In the presence of pseudoplatelets, the automated platelet count should be corrected. In our present study, the platelet counts had to be corrected in more than 25% of the patients investigated. Because in almost 5% of the patients this resulted in a re-classification of the bleeding risk, the finding of pseudoplatelets has important consequences for the clinical management of patients with acute leukaemia. 
Take home messages
• Pseudoplatelets were found in the blood smears of 43 (25%) of the 169 patients with leukaemia and in almost 5% of the patients this resulted in a re-classification of the bleeding risk • The finding of pseudoplatelets has important consequences for the clinical management of patients with acute leukaemia • Platelets should be determined morphologically in patients with acute leukaemia • There is a need for a routine screening method for the detection of pseudoplatelets
